Mediar Therapeutics Secures $76M to Accelerate Anti-Fibrosis Therapies for Skin, Lung, and Kidney Diseases

A $76 million funding surge for Mediar Therapeutics signals a bold bid to reframe how aging and chronic disease are fought—by targeting the scarring that silently undermines organs.

Mediar Therapeutics recently closed an oversubscribed $76 million Series B funding round co-led by Amplitude Ventures and ICG, with participation from Longwood Fund, Asahi Kasei Pharma Ventures, and Alexandria Real Estate Equities.

The funding will advance anti-fibrotic therapies targeting fibrotic diseases in the skin, lung, and kidney.

MTX-474, the company’s systemic sclerosis candidate, is currently in Phase 2a trials with approximately 90 patients enrolled in the EncompaSSc study. Meanwhile, MTX-463, an idiopathic pulmonary fibrosis candidate, is being developed through a $99 million upfront collaboration with Eli Lilly.

The third therapy, MTX-439 for kidney fibrosis, is scheduled to enter Phase 1 studies in 2026.

Rahul Ballal, CEO of Mediar Therapeutics, said:

"With $175 million raised through these transactions, we can advance our novel anti-fibrotics through clinical studies and potentially bring life-changing therapies to patients suffering from fibrosing diseases of the skin, lung and kidney."

Dr. Lorinda Chung, who is overseeing the Phase 2a trial for MTX-474, said:

"Patients with SSc face a large unmet need, and this Phase 2a trial will allow us to see if MTX-474 can make a meaningful difference in their lives."

Dr. Allan Marchington of ICG commented:

"Mediar’s approach to the underlying causes of fibrosis is setting the stage for major clinical breakthroughs."

Dr. Bharat Srinivasa of Amplitude Ventures added:

"The organization intends to apply its scientific knowledge to develop life-changing patient therapies."

The therapies focus on inhibiting myofibroblasts, which play a central role in fibrotic disease progression. While early-stage results are promising, these findings remain preliminary and require further validation in larger clinical trials before potential clinical application.

⚠️ LEGAL DISCLAIMER: It is for informational purposes only. It never substitutes for professional medical advice, diagnosis, or treatment. Always consult your doctor regarding any questions about your health.